GlassScriptPhysician profile
Youram Nassir
NPI 1114977071
$25,358.83
in general payments reported to CMS, 2019-2025
82 companies · $5,097 in 2025
The $5,097 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,243 · 2020: $2,340 · 2021: $3,309 · 2022: $3,489 · 2023: $3,719 · 2024: $4,162 · 2025: $5,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,706.63 |
| Education | $271.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,595.03 | 2019-2025 | Opdivo, Opdualag, Abecma |
| Astrazeneca Pharmaceuticals LP | $2,283.52 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Pfizer INC. | $2,051.85 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,930.68 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $1,573.84 | 2019-2025 | Carvykti, Tecvayli, Rybrevant |
| Incyte Corporation | $1,031.77 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Genzyme Corporation | $958.03 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $767.95 | 2019-2025 | |
| Astellas Pharma US INC | $713.90 | 2019-2025 | Vyloy, Xospata, Padcev |
| Genentech USA, INC. | $681.00 | 2019-2025 | Tecentriq, Polivy |
| Ipsen Biopharmaceuticals, INC | $646.60 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
| Celgene Corporation | $584.37 | 2019-2025 | Reblozyl, Breyanzi, Opdualag |
| Eisai INC. | $536.36 | 2019-2025 | |
| Seagen INC. | $468.27 | 2020-2025 | Adcetris, Padcev |
| Daiichi Sankyo INC. | $457.11 | 2020-2025 | Enhertu, Datroway |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youram Nassir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.